Sitagliptin and cardiovascular outcomes in type 2 diabetes - author's reply

Sitagliptin and cardiovascular outcomes in type 2 diabetes - author's reply

Dettagli Bibliografici
Autori principali:	Holman, RR, Peterson, ED
Natura:	Journal article
Lingua:	English
Pubblicazione:	Massachusetts Medical Society 2015

Documenti analoghi

Correspondence on sitagliptin and cardiovascular outcomes in type 2 diabetes
di: Holman, R, et al.
Pubblicazione: (2015)

Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes--Authors' reply.
di: Holman, R, et al.
Pubblicazione: (2014)

Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS.
di: Cornel, J, et al.
Pubblicazione: (2016)

Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes - authors' reply
di: Nazarzadeh, M, et al.
Pubblicazione: (2022)

Assessing the safety of sitagliptin in older participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
di: Bethel, M, et al.
Pubblicazione: (2017)

Microvascular outcomes in type 2 diabetes - Authors' reply
di: Zoungas, S, et al.
Pubblicazione: (2017)

Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: Outcomes from TECOS.
di: Engel, S, et al.
Pubblicazione: (2017)

Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
di: Bethel, M, et al.
Pubblicazione: (2009)

Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
di: Reed, S, et al.
Pubblicazione: (2018)

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
di: Green, J, et al.
Pubblicazione: (2013)

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
di: Green, J, et al.
Pubblicazione: (2013)

Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS Trial.
di: Josse, R, et al.
Pubblicazione: (2016)

Effect of sitagliptin on proteinuria in patients with type 2 diabetes - A renoprotective effect of sitagliptin
Pubblicazione: (2021-01-01)

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
di: Engel Samuel S, et al.
Pubblicazione: (2013-01-01)

The authors reply
di: Holman, R, et al.
Pubblicazione: (2010)

Dapagliflozin combined with sitagliptin in treatment of type 2 diabetes
di: CHEN Hui, et al.
Pubblicazione: (2024-03-01)

METFORMIN IN THE MANAGEMENT OF TYPE-2 DIABETES - REPLY
di: Holman, R, et al.
Pubblicazione: (1989)

Insulin Regimens in Type 2 Diabetes REPLY
di: Holman, R, et al.
Pubblicazione: (2010)

Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan.
di: Szu-Heng Wang, et al.
Pubblicazione: (2015-01-01)

The authors reply
di: Holman, R, et al.
Pubblicazione: (2009)

The authors reply
di: Holman, R, et al.
Pubblicazione: (2008)

The authors reply
di: Holman, R, et al.
Pubblicazione: (2010)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
di: Shannon A Miller, et al.
Pubblicazione: (2009-05-01)

The durability of sitagliptin in elderly patients with type 2 diabetes
di: Hsieh CJ, et al.
Pubblicazione: (2014-11-01)

Calculation of coronary risk in Type II diabetes: another cause for concern: authors' reply
di: Holman, R, et al.
Pubblicazione: (2002)

The author replies
di: Peterson Christopher
Pubblicazione: (1998-01-01)

Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients
di: Antonio Asti, et al.
Pubblicazione: (2016-03-01)

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
di: Jonathan K Reynolds
Pubblicazione: (2009-07-01)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
di: Ahren B
Pubblicazione: (2010-03-01)

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
di: Omoto S, et al.
Pubblicazione: (2015-07-01)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
di: Bo Ahr&eacute;n
Pubblicazione: (2010-03-01)

Review of sitagliptin phosphate: a novel treatment for type 2 diabetes
di: Baptist Gallwitz
Pubblicazione: (2007-05-01)

Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus
di: Ji Hyun Kim
Pubblicazione: (2015-08-01)

The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes
di: Suvanjaa Sivalingam, et al.
Pubblicazione: (2021-05-01)

Estimating cardiovascular risk and all-cause mortality in individuals with type 2 diabetes using the UKPDS Outcomes Model
di: Coleman, RL, et al.
Pubblicazione: (2019)

Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial
di: McGuire, D, et al.
Pubblicazione: (2016)

Expert Opinion on Fixed Dose Combination of Dapagliflozin Plus Sitagliptin for Unmet Cardiovascular Benefits in Type 2 Diabetes Mellitus
di: Soumitra Ray, et al.
Pubblicazione: (2024-04-01)

The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study
di: Shin S, et al.
Pubblicazione: (2016-03-01)

Addition of insulin to oral therapy in type 2 diabetes - Reply
di: Holman, R, et al.
Pubblicazione: (2008)

Genome-Wide Transcriptome Analysis in Type 2 Diabetes Patients Treated by Sitagliptin
di: Ma R, et al.
Pubblicazione: (2022-06-01)